{"id":"W4415749836","doi":"10.1200/oa-25-00099","title":"Alliance A022106: A Phase II/III Trial of Nab-Paclitaxel and Gemcitabine ± Cisplatin as Second-Line Treatment for <i>BRCA1/2</i> or <i>PALB2</i> Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)","year":2025,"lang":"en","type":"article","venue":"JCO oncology advances.","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Gemcitabine; Pancreatic ductal adenocarcinoma; Cisplatin; Mutant; Pancreatic cancer; Adenocarcinoma; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001475148,0.001343729,0.001312014,0.0005502339,0.0004033171,0.001267744,0.001202968,0.001456033,0.008488237],"category_scores_gemma":[0.0007868913,0.0004632686,0.001264371,0.0005530753,0.0008178279,0.001179487,0.0005955404,0.003940673,0.001948852],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009203666,"about_ca_system_score_gemma":0.001703413,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001593477,"about_ca_topic_score_gemma":0.004567206,"domain_scores_codex":[0.9997007,0.0001341108,0.00001534857,0.00005463809,0.00002899702,0.00006630808],"domain_scores_gemma":[0.9995294,0.00005629192,0.00007495407,0.00003635901,0.00002210482,0.0002809096],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5828263,0.06749444,0.006502569,0.001866675,0.002674492,0.0004102378,0.0003859948,0.005823356,0.03126803,0.002053217,0.03962372,0.259071],"study_design_scores_gemma":[0.7618548,0.2077027,0.007889831,0.0001351968,0.0006705732,0.0006289787,0.0001374945,0.002685082,0.002928243,0.001091859,0.01422297,0.00005224224],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9659007,0.005236072,0.00114781,0.002506075,0.0007627553,0.003906821,0.006118467,0.0007852734,0.01363607],"genre_scores_gemma":[0.9501982,0.005985453,0.004967245,0.004768869,0.0003590551,0.004880995,0.01431085,0.0001911346,0.01433825],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008488237,"threshold_uncertainty_score":0.02839601,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05262911651944999,"score_gpt":0.4200712748728941,"score_spread":0.3674421583534441,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}